【2024 ASH】TransThera Announces the Phase I Study Results of TT-01488, a Novel Non-Covalent BTK Inhibitor, in Patients with Relapsed or Refractory B-cell Malignancies
NANJING,China and GAITHERSBURG,Md.,Dec. 10,2024--TransThera Sciences (Nanjing),Inc. (the "TransThera"),a clinical demand-oriented,registrational clinical stage biopharmaceutical company focu